HOME › Research Insight › Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Dominate Drug Market
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Dominate Drug Market
In 2013, the U.S. dominates the acute lymphocytic/lymphoblastic leukemia therapeutics market in G8 countries; it will continue to drive and dominate this market over the forecast period (2013 to 2020). The growth in the Germany and U.K. markets will primarily be driven by increasing prevalence of disease and growth in health care spending in respective countries.
Acute lymphocytic/lymphoblastic leukemia therapeutics Market: Linker regimen will continue to lead the therapeutics market from 2013 to 2020.
By 2020, Linker regimen will continue to dominate the acute lymphocytic/lymphoblastic leukemia therapeutics market. Among existing regimen and drugs markets, Oncaspar, a drug from Sigma-tau Pharmaceuticals is poised to grow at the highest CAGR from 2013 to 2020. The Oncaspar market is expected to grow at a CAGR of 8.1% from 2015 to 2020, to reach $74.3 million by 2020.
Upon their launch, all the drugs that are currently under pipeline are expected to grow at a CAGR that is estimated to be greater than 40%. Among these drugs, Marqibo will lead the market for newly launched drugs from 2013 to 2020.
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020).
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252